NLRP3 and arrhythmogenic right ventricular cardiomyopathy: Then we explored the effects of NLRP3-targeted therapy in a ARVC model by infusing MCC950, a diarylsulfonylurea-containing compound that was shown to selectively inhibit the oligomerization and activation of the NLRP3 inflammasome in response to canonical and non-canonical stimuli [32].